BeOne Medicines Ltd.

BeOne Medicines Ltd. (Nasdaq: BEON; HKEx: 06160) is a global oncology company engaged in discovering, developing, and commercializing innovative cancer treatments designed to be more accessible to patients worldwide. The company operates through a fully integrated business model with approximately 12,000 employees across six continents, supported by a substantial clinical development team of roughly 3,800 people and a research organization of over 1,200 scientists.

The company's commercial portfolio is anchored by two primary internally developed medicines. BRUKINSA, a Bruton's tyrosine kinase inhibitor approved in 77 markets including the United States, European Union, China, and Japan, addresses multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and follicular lymphoma. TEVIMBRA, a humanized anti-PD-1 monoclonal antibody, is approved in 51 markets for various solid tumors and has achieved broad reimbursement across multiple indications in China, Europe, Japan, and the United States. The company also commercializes in-licensed products from partners including Amgen, Jazz Pharmaceuticals, Zymeworks, and others, primarily in China and select international markets.

BeOne maintains a differentiated competitive position through its proprietary clinical development infrastructure that operates largely independent of traditional contract research organizations, enabling faster and more cost-efficient drug development. The company has invested in diverse technology platforms spanning small molecules, protein degraders, bispecific antibodies, and antibody-drug conjugates. Its pipeline includes over 20 programs in various development stages, with particular focus on hematologic malignancies and solid tumors including breast, lung, and gastrointestinal cancers.

The company was founded in 2010 and redomiciled from the Cayman Islands to Switzerland in the second quarter of 2025. BeOne maintains commercial operations and manufacturing capabilities across the United States, China, the United Kingdom, and Australia, with a geographically diversified revenue base spanning North America, Europe, and Asia-Pacific regions. The company's business model emphasizes sustainable returns on research and development investment through integrated operations and strategic partnerships.